MediWound Ltd. (NASDAQ:MDWD – Get Rating) was the target of a large decline in short interest in April. As of April 30th, there was short interest totalling 54,800 shares, a decline of 30.6% from the April 15th total of 79,000 shares. Approximately 0.3% of the company’s stock are sold short. Based on an average trading volume of 116,100 shares, the short-interest ratio is currently 0.5 days.
A number of institutional investors have recently added to or reduced their stakes in the business. Sargent Investment Group LLC raised its position in shares of MediWound by 2.5% during the first quarter. Sargent Investment Group LLC now owns 374,750 shares of the biopharmaceutical company’s stock valued at $746,000 after buying an additional 9,000 shares during the last quarter. Morgan Stanley raised its position in shares of MediWound by 12.4% during the third quarter. Morgan Stanley now owns 85,947 shares of the biopharmaceutical company’s stock valued at $287,000 after buying an additional 9,497 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of MediWound during the third quarter valued at about $38,000. Goldman Sachs Group Inc. acquired a new position in shares of MediWound during the third quarter valued at about $48,000. Finally, Marshall Wace LLP acquired a new position in shares of MediWound during the first quarter valued at about $93,000. 13.58% of the stock is owned by hedge funds and other institutional investors.
MediWound stock traded down $0.03 on Friday, reaching $1.88. 46,220 shares of the stock were exchanged, compared to its average volume of 114,165. The stock has a market cap of $62.19 million, a PE ratio of -3.84 and a beta of 1.24. MediWound has a twelve month low of $1.25 and a twelve month high of $6.22. The firm has a fifty day moving average price of $2.02 and a two-hundred day moving average price of $2.41.
Several equities research analysts recently issued reports on the stock. Aegis reduced their price objective on shares of MediWound from $9.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, March 21st. StockNews.com assumed coverage on shares of MediWound in a research note on Friday. They issued a “sell” rating for the company. Finally, Zacks Investment Research lowered shares of MediWound from a “buy” rating to a “hold” rating in a research note on Saturday, March 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $5.69.
MediWound Company Profile (Get Rating)
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
- Get a free copy of the StockNews.com research report on MediWound (MDWD)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.